Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Expects 62 Percent Rise in Q4 Revenues

NEW YORK (GenomeWeb) – WaferGen Bio-systems announced today that it expects to report a 62 percent rise in fourth quarter revenues while meeting its full-year revenue guidance.

For the three-month period ended Dec. 31, WaferGen's revenues are expected to be $3.9 million compared with $2.4 million in the same period the year before. The company said its revenues for 2016 are expected to be approximately $10.7 million, in line with previous guidance of $10 million to $12 million.

WaferGen said that it ended 2016 with about $4.5 million in cash, including a $2.5 million deposit received from Takara Bio USA Holdings pursuant to the companies' merger agreement announced last year.

Under the terms of the deal, WaferGen's purchase price would be based on a multiple between one and three-and-a-half times of its full-year 2016 revenues, with the multiple capped at three-and-a-half times if those revenues exceed $9 million. Based on the company's revenue projections, the merger is valued at roughly $37.5 million including the deposit. It is expected to close by next month.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more